Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of etrasimod in moderately to severely active ulcerative colitis
MOH_2019-12-02_008531Phase 3Active, not recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Long-term safety. Started Jul 2019; status: active, not recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-12-02_008531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-02_008531.